437 related articles for article (PubMed ID: 29400292)
1. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
[No Abstract] [Full Text] [Related]
2. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
3. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
4. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136
[No Abstract] [Full Text] [Related]
5. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
6. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
7. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
8. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
[No Abstract] [Full Text] [Related]
9. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
10. Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
Mangana J; Buset CS; Dummer R
JAMA Oncol; 2019 May; 5(5):730-731. PubMed ID: 30676614
[No Abstract] [Full Text] [Related]
11. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
[No Abstract] [Full Text] [Related]
12. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
13. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
Korman AM; Tyler KH; Kaffenberger BH
Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
[No Abstract] [Full Text] [Related]
14. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
15. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
18. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
19. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
20. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]